APLS vs RMD · rev $1.00B vs P/E 29, rev $5.65B
Apellis Pharmaceuticals Inc (APLS) versus ResMed Inc (RMD) — a side-by-side from cached financials, not a winner call.
Apellis Pharmaceuticals Inc (APLS) is a biotechnology company listed on US.
ResMed Inc (RMD) is a medical instruments & supplies company listed on US.
Latest reported APLS revenue for 2025-12-31 was $1.00B. Net income was $22.4M. Revenue was up 28.5% from 2024-12-31 to 2025-12-31. APLS currently screens at market cap $2.29B.
Latest reported RMD revenue for 2026-06-30 was $5.65B. Net income was $1.52B. Revenue was up 9.9% from 2025-06-30 to 2026-06-30. RMD currently screens at market cap $37.68B and trailing P/E 28.8.
APLS currently screens at market cap $2.29B. RMD currently screens at market cap $37.68B and trailing P/E 28.8.
Not investment advice. Open the APLS and RMD stock pages for the full models.
Not investment advice.